骨髓增殖性肿瘤中PPM1D过表达的分子后果与靶向治疗
该研究对519例MPN患者测序,发现3.1%携带PPM1D激活突变,多数野生型病例中PPM1D过表达。单细胞分析显示PPM1D突变改变TP53、DNA损伤反应和细胞周期调控,并上调MYC、mTORC1、OXPHOS、JAK/STAT和NF-κB通路。PPM1D抑制剂GSK2830371联合低剂量HDM2抑制可优先靶向JAK2V617F+ HSPCs,在骨髓纤维化样本中减少突变克隆并降低白血病负荷。
要点
- MPN患者中PPM1D激活突变率为3.1%,多数野生型病例PPM1D过表达
- PPM1D突变HSPCs中TP53、DNA损伤反应和细胞周期调控改变
- PPM1D抑制剂联合HDM2抑制可靶向JAK2V617F+ HSPCs并减少突变克隆
核心结论
- PPM1D是MPN造血干祖细胞的关键调控因子,双靶向PPM1D/HDM2是骨髓纤维化的潜在治疗策略。
研究设计与样本
- 对519例MPN患者进行测序,检测PPM1D激活突变频率。
- 从MPN患者构建同源JAK2V617F+/PPM1D-WT和JAK2V617F+/PPM1D-MUT诱导多能干细胞系。
- 对iPSC来源HSPCs及原代PPM1D-MUT MPN患者单核细胞进行单细胞RNA测序。
- 在骨髓纤维化样本中测试PPM1D抑制剂GSK2830371单药及联合低剂量HDM2抑制。
- 在异种移植MPN模型中验证双靶向PPM1D和HDM2的疗效。
主要发现
- 519例MPN患者中3.1%检测到PPM1D激活突变,多数PPM1D野生型MPN病例HSPCs中PPM1D过表达。
- iPSC来源HSPCs单细胞RNA测序显示TP53、DNA损伤反应和细胞周期调控改变。
- 原代PPM1D-MUT MPN患者MNCs单细胞RNA测序证实HSCs中MYC、mTORC1、OXPHOS、JAK/STAT和NF-κB通路及相关基因上调。
- GSK2830371优先抑制骨髓纤维化样本的集落形成。
- GSK2830371联合低剂量HDM2抑制显著改善对JAK2V617F+ HSPCs的靶向并保护正常HSPCs;克隆复杂MF患者样本中突变克隆减少、野生型克隆增加>4倍;异种移植MPN模型白血病负荷显著降低。
临床怎么用
- 对MPN患者可考虑检测PPM1D突变及过表达状态以识别潜在靶向治疗人群。
- 骨髓纤维化患者中PPM1D抑制剂联合HDM2抑制可能作为清除JAK2V617F+ HSPCs的策略,但需临床验证。
局限性
- PPM1D突变频率基于519例MPN患者测序,需更大样本验证。
- 双靶向策略的疗效主要在体外骨髓纤维化样本和异种移植模型中观察,尚未在临床试验中评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Phosphatase Mg2+/Mn2+ dependent 1D protein (PPM1D) is a serine threonine phosphatase known to regulate oncogenic pathways. PPM1D mutations are enriched in therapy-related MDS and AML, but the role of PPM1D in myeloproliferative neoplasms (MPN) remains largely unexplored. By sequencing 519 MPN patients, we detected activating PPM1D mutations in 3.1% of them. Importantly, PPM1D was overexpressed in hematopoietic stem and progenitor cells (HSPCs) in most PPM1D wild-type (WT) MPN cases. To elucidate the impact of PPM1D mutations on MPN HSPCs, we generated isogenic JAK2V617F+/PPM1D-WT and JAK2V617F+/PPM1D mutant (MUT) induced pluripotent stem cell (iPSC) lines from a MPN patient. Single-cell RNA-sequencing (scRNA-seq) of iPSC derived HSPCs revealed altered TP53, DNA damage response and cell cycle regulation. scRNA-seq analysis of primary PPM1D-MUT MPN patient mononuclear cells (MNCs) further confirmed upregulation of MYC, mTORC1, OXPHOS, JAK/STAT, and NF-κB pathways and corresponding genes in HSCs. The allosteric PPM1D inhibitor (PPM1Di) GSK2830371 preferentially inhibited colony formation in myelofibrosis (MF) samples. Combination treatment of GSK2830371 with low dose inhibition of HDM2, a negative regulator of p53, significantly improved targeting of JAK2V617F+ HSPCs, while sparing normal HSPCs. Single-cell mutational and protein analysis of a clonally complex MF patient sample treated with this combination strategy revealed reduced mutated clones and increased WT clones by >4-fold. Dual PPM1D and HDM2 targeting also significantly decreased leukemic burden in a xenograft MPN model. These findings support PPM1D as a critical MPN HSPCs regulator and support dual PPM1D/HDM2 inhibition as a treatment strategy for MF patients.
引用
- Mia MB, Schaniel C, Clementelli C, et al. Molecular Consequences and Targeting of PPM1D Overexpression in Myeloproliferative Neoplasms. Blood. 2026. PMID: 42868262. doi:10.1182/blood.2025030377
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。